Pfizer (PFE) Enters Settlement with Impax (IPXL) Over Detrol LA Application
Tweet Send to a FriendGet Alerts PFE Hot Sheet
Price: $29.38 +2.08%
Overall Analyst Rating:
BUY (
Up)
Dividend Yield: 3.5%
Revenue Growth %: -12.3%
Overall Analyst Rating:
BUY (
Up)Dividend Yield: 3.5%
Revenue Growth %: -12.3%
Trade PFE Now!
Pfizer Inc. (NYSE: PFE) is ticking higher in late trading Thursday following reports that it settled litigation with Impax Labs (Nasdaq: IPXL).
According to Bloomberg, Pfizer and Impax settled a patent lawsuit over an application for the generic form of Detrol LA.
Detrol LA is a bladder-control treatment.
Terms of the settlement weren't disclosed.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
According to Bloomberg, Pfizer and Impax settled a patent lawsuit over an application for the generic form of Detrol LA.
Detrol LA is a bladder-control treatment.
Terms of the settlement weren't disclosed.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Pfizer (PFE) to Split Off Remaining Interest in Zoetis (ZTS)
- Nokia Siemens (NOK) (SI) Enhances Smart Wi-Fi, Launches 3G Femtocell Access Point
- AcelRx Pharma (ACRX) Stock Higher; Sufentanil NanoTab Study Meets Primary Endpoint
Create E-mail Alert Related Categories
Corporate News, FDA, Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
